

Xspray Pharma

Healthcare

23 April 2026

Summer PDUFA dates put launch within reach

Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer. The oversubscribed rights issue (securing SEK113m in gross proceeds) will remove the principal financing overhang, and any future financing needs are likely to be non-dilutive, underpinned by target cash flow break-even following the successful execution of product launches. We believe the combination of resolved financing, advancing commercial readiness and two imminent binary catalysts represents a potentially de-risking moment for the stock.

Dual catalysts and clinical differentiation

XS003 (formulation of nilotinib) has a PDUFA date of 18 June 2026, followed by Dasynoc (formulation of dasatinib) on 25 August 2026. Together, the candidates address a c \$2.7bn US market in chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia. We see the clinical profile of both as robust. Dasynoc offers bioequivalence at a 30% lower dose, with compatibility with proton pump inhibitors (PPIs), a meaningful advantage given widespread PPI co-prescription in the CML population. XS003 achieves comparable bioavailability at less than half the nilotinib dose and dramatically reduces the food interaction that carries a boxed warning on the reference product. Shared commercial infrastructure may underpin an efficient and coordinated dual launch. In our view, this represents a compelling source of operating leverage as Xspray moves towards first potential revenues.

Financing overhang cleared

The rights issue initially included an SEK83m raise, with an over-allotment option of SEK30m, confirmed as fully utilised on 23 April 2026. With net cash of SEK32m at end-2025 and rights issue proceeds incoming, Xspray enters its pivotal regulatory window with a sufficiently capitalised balance sheet. Guidance that proceeds should cover working capital requirements through 2026 assumes approval and launch of both lead assets, a base case we consider credible given the differentiated clinical data and groundwork laid with US key opinion leaders during the extended review period.

Valuation: Binary catalysts approaching

The stock currently trades at a significant discount to analyst consensus (c SEK60/ share), reflecting residual regulatory risk following the October 2025 CRL for Dasynoc, though the accepted resubmission in March 2026 should largely offset this risk. We see two clear re-rating triggers: approval of XS003 would validate the HyNap platform and unlock the first revenue stream, while Dasynoc approval would complete the dual-launch thesis. Beyond the lead assets, Xspray's broader pipeline provides longer-term optionality that the current market capitalisation is yet to reflect.


Historical financials

Year end	Revenue (SEKm)	PBT (SEKm)	EPS (SEK)	DPS (SEK)	P/E (x)	Yield (%)
12/24	0.0	(285.7)	(8.62)	0.00	N/A	N/A
12/25	0.0	(171.5)	(4.46)	0.00	N/A	N/A

Source: Company documents

Price SEK28.50
Market cap SEK1,308m

Share price performance



Share details

Code	XSPRAY
Listing	OMX
Shares in issue	45.9m
Net cash at end-December 2025	SEK32.0m

Business description

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development utilising its innovative, patent-protected HyNap technology platform to create improved versions of marketed protein kinase inhibitors.

Bull points

- Two near-term PDUFA dates (June and August 2026) offer sequential re-rating catalysts.
- Differentiated formulations with improved patient adherence profiles versus reference products.
- HyNap platform scalability provides a robust longer-term pipeline.

Bear points

- Regulatory risks: a complete response letter (CRL) for either product would trigger a share price decline and further financing needs.
- GMP issues at the third-party Italian contract manufacturer remain under remediation.
- Commercial-stage execution risk: first-time launch into competitive markets.

Analysts

Arron Aatkar, PhD	+44 (0)20 3077 5700
Jyoti Prakash, CFA	+44 (0)20 3077 5700
Pooya Hemami, OD MBA,	+44 (0)20 3077 5700
CFA	

healthcare@edisongroup.com
[Edison profile page](#)

EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
